Helix BioPharma receives approval to initiate Phase II pharmacokinetic clinical study of topical Interferon Alpha-2b in patients with low-grade cervical lesions.

Helix BioPharma Corp has received the necessary regulatory approvals in Germany to initiate its planned Phase II pharmacokinetic study of Topical Interferon Alpha-2b in patients with low-grade cervical lesions. The clinical study was designed, as mandated by regulatory authorities, to gather data on the absorption and elimination profile of Topical Interferon Alpha-2b in patients with low-grade cervical lesions, in addition to further data on its safety and efficacy. Depending on the data generated in the study, it is expected that interim results, which Helix anticipates will be received during its fiscal 4Q 2009, will allow the company to proceed with its planned regulatory …